Balanced news tone
News Sentiment
001067 sentiment intelligence
JW Pharmaceutical Corporation news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
46
Balanced news tone
15 relevant articles
News tone and price action are not far from neutral.
86/100 classification confidence.
directly relevant articles
high-authority source matches
-1.1% over one week, -10.5% over four weeks, trend inactive, and below fair value.
JW Pharmaceutical's Livalo-Zet Tops Dyslipidemia Combination Drug Market
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
86/100 classification
One-week reaction
-1.1%
Price digesting
Trend fit
Trend inactive
-10.5% over four weeks
Fair value
-23.5%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
0
Neutral
11
Negative
4
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Seoul Economic Daily
Direct company coverage
JW Pharmaceutical's Livalo-Zet Tops Dyslipidemia Combination Drug Market
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 06:14
- Source
- Seoul Economic Daily
Seoul Economic Daily
Direct company coverage
Hair Loss Insurance Hopes Send JW Pharmaceutical, TS Trillion to Daily Limit
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 15 Jun 2026 02:13
- Source
- Seoul Economic Daily
Business Wire
Direct company coverage
JW Pharmaceutical Presents Preclinical Results and Global Development Strategy for DDC-02, a Novel Therapeutic Candidate for Rare Neurodevelopmental Disorders
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 Jun 2026 13:00
- Source
- Business Wire
koreabiomed.com
Direct company coverage
JW Pharmaceutical finishes phase 3 dosing for epaminurad, data due this year
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Apr 2026 07:00
- Source
- koreabiomed.com
Pharmaceutical Technology
Direct company coverage
Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Apr 2026 07:00
- Source
- Pharmaceutical Technology
PR Newswire
Direct company coverage
Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Apr 2026 07:00
- Source
- PR Newswire
The Korea Herald
Direct company coverage
JW Pharmaceutical secures GLP-1 drug rights in $81m deal
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 09 Apr 2026 07:00
- Source
- The Korea Herald
Seoul Economic Daily
Direct company coverage
JW Pharmaceutical Stock Rises on Exclusive Obesity Drug Licensing Deal
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 09 Apr 2026 07:00
- Source
- Seoul Economic Daily
koreabiomed.com
Direct company coverage
JW Pharmaceutical signs $81 mil. license-in deal with China's Gan & Lee for GLP-1 obesity drug
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 09 Apr 2026 07:00
- Source
- koreabiomed.com
Chosunbiz
Direct company coverage
JW Pharmaceutical advances fourth-generation leadership as Korea hair loss drug enters trials - CHOSUNBIZ
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 27 Mar 2026 07:00
- Source
- Chosunbiz
koreabiomed.com
Direct company coverage
JW Pharmaceutical OKed for phase 1 novel hair loss drug trial
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 13 Feb 2026 08:00
- Source
- koreabiomed.com
koreabiomed.com
Direct company coverage
JW Pharmaceutical shares real-world prescribing data for immune thrombocytopenia drug Tavalisse
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jan 2026 08:00
- Source
- koreabiomed.com
조선일보
Direct company coverage
JW Pharmaceutical Registers U.S. Patent for Hair Loss Treatment JW0061
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 19 Jan 2026 08:00
- Source
- 조선일보
koreabiomed.com
Direct company coverage
JW Pharmaceutical rolls out dual-action dyslipidemia therapy Livalo Feno
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jan 2026 08:00
- Source
- koreabiomed.com
koreabiomed.com
Direct company coverage
JW Pharmaceutical’s Hemlibra earns spot on WHO’s 2025 essential medicines list for hemophilia A
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Oct 2025 07:00
- Source
- koreabiomed.com